Prognosis and Life Expectancy in Behçet's Disease

General Prognosis and Life Expectancy

Behçet's disease typically follows a relapsing and remitting course, with disease manifestations that often ameliorate over time in many patients, according to the European League Against Rheumatism 1
Ocular, vascular, neurological, and gastrointestinal involvement are associated with poor prognosis and can cause serious damage or death if left untreated, as stated by the European League Against Rheumatism 1
When only skin, mucosa, and joint involvement are present, the prognosis is generally good and does not cause permanent damage, as reported by the European League Against Rheumatism 1
Young men with early disease onset have a more severe disease course, requiring more aggressive treatment and careful follow-up, according to the European League Against Rheumatism 1

For parenchymal NBD, treatment options include high-dose intravenous methylprednisolone followed by oral tapering, along with immunosuppressants such as azathioprine, cyclophosphamide, interferon-alpha, or TNF-alpha inhibitors, as recommended by the American College of Rheumatology 3
Cyclosporine A should be avoided in patients with CNS involvement due to potential neurotoxicity, as advised by the American College of Rheumatology 4

Regular monitoring of disease activity through clinical symptoms and inflammatory markers is essential, as emphasized by the American College of Rheumatology 4
For patients with ocular involvement, regular ophthalmologic examinations are crucial, as recommended by the American College of Rheumatology 4

Young men with early disease onset have a higher risk of severe disease and may benefit from early systemic immunosuppression, as suggested by the American College of Rheumatology 4
Post-thrombotic syndrome is frequent with recurrent deep vein thrombosis and may result in difficult-to-treat leg ulcers, as noted by the American College of Rheumatology 4